Patents by Inventor Andrew E. Spaulding

Andrew E. Spaulding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oral complement factor D inhibitors
    Patent number: 12558341
    Abstract: Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: February 24, 2026
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Andrew E. Spaulding, Wei Lv, Zhao Dang, Krishnan Raman
  • ORAL COMPLEMENT FACTOR D INHIBITORS
    Publication number: 20250275991
    Abstract: Disclosed are compounds of formula (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Application
    Filed: October 9, 2020
    Publication date: September 4, 2025
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng LU, Andrew E. Spaulding, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Krishnan Raman
  • ORAL COMPLEMENT FACTOR D INHIBITORS
    Publication number: 20250186391
    Abstract: Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Application
    Filed: October 9, 2020
    Publication date: June 12, 2025
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Andrew E. Spaulding, Wei Lv, Zhao Dang, Krishnan Raman
  • IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE
    Publication number: 20240270750
    Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: May 24, 2022
    Publication date: August 15, 2024
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Wei Lv, Peng-Cheng Lu, Andrew E. Spaulding, Krishnan Raman